IL251778B - Novel pyrazolopyrimidine histories as nik inhibitors - Google Patents

Novel pyrazolopyrimidine histories as nik inhibitors

Info

Publication number
IL251778B
IL251778B IL251778A IL25177817A IL251778B IL 251778 B IL251778 B IL 251778B IL 251778 A IL251778 A IL 251778A IL 25177817 A IL25177817 A IL 25177817A IL 251778 B IL251778 B IL 251778B
Authority
IL
Israel
Prior art keywords
pyrazolopyrimidine derivatives
nik inhibitors
new
new pyrazolopyrimidine
nik
Prior art date
Application number
IL251778A
Other languages
English (en)
Hebrew (he)
Other versions
IL251778A0 (en
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL251778A0 publication Critical patent/IL251778A0/en
Publication of IL251778B publication Critical patent/IL251778B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL251778A 2014-10-23 2017-04-19 Novel pyrazolopyrimidine histories as nik inhibitors IL251778B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14190073 2014-10-23
PCT/EP2015/074431 WO2016062790A1 (en) 2014-10-23 2015-10-22 New pyrazolopyrimidine derivatives as nik inhibitors

Publications (2)

Publication Number Publication Date
IL251778A0 IL251778A0 (en) 2017-06-29
IL251778B true IL251778B (en) 2020-10-29

Family

ID=51846471

Family Applications (1)

Application Number Title Priority Date Filing Date
IL251778A IL251778B (en) 2014-10-23 2017-04-19 Novel pyrazolopyrimidine histories as nik inhibitors

Country Status (13)

Country Link
US (2) US10221180B2 (OSRAM)
EP (1) EP3209663B1 (OSRAM)
JP (1) JP6616412B2 (OSRAM)
KR (1) KR102523405B1 (OSRAM)
CN (1) CN107074882B (OSRAM)
AU (1) AU2015334915B2 (OSRAM)
BR (1) BR112017007704B1 (OSRAM)
CA (1) CA2960574C (OSRAM)
EA (1) EA033237B1 (OSRAM)
ES (1) ES2715104T3 (OSRAM)
IL (1) IL251778B (OSRAM)
MX (1) MX371152B (OSRAM)
WO (1) WO2016062790A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為NIK抑制劑的新穎3-(1H-吡唑-4-基)-1H-吡咯并[2,3-c]吡啶衍生物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作NIK抑制劑之新的1-(4-嘧啶基)-1H-吡唑並[3,2-c]吡啶衍生物
CA2960335C (en) 2014-10-23 2023-09-19 Janssen Pharmaceutica Nv New pyrazole derivatives as nik inhibitors
EA030908B1 (ru) 2014-10-23 2018-10-31 Янссен Фармацевтика Нв Соединения в качестве ингибиторов nik
MX371151B (es) 2014-10-23 2020-01-20 Janssen Pharmaceutica Nv NUEVOS DERIVADOS DE TIENOPIRIMIDINA EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK).
ES2715104T3 (es) 2014-10-23 2019-05-31 Janssen Pharmaceutica Nv Nuevos derivados de pirazolopirimidina como inhibidores de nik
US12448374B2 (en) 2018-06-07 2025-10-21 Disarm Therapeutics, Inc. Inhibitors of SARM1
EA202092962A1 (ru) * 2018-06-18 2021-09-06 Янссен Фармацевтика Нв Производные пиразола в качестве ингибиторов malt1
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
CN113613729A (zh) * 2019-03-29 2021-11-05 兴和株式会社 新型氮杂吲哚衍生物
MX2021014679A (es) 2019-05-31 2022-04-06 Janssen Pharmaceutica Nv Inhibidores de molécula pequeña de quinasa inductora de nf-kb.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007926A1 (en) * 1989-01-20 1990-07-26 Pfizer Inc. 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines
CA2564356A1 (en) 2004-04-26 2005-11-03 Pfizer Inc. Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors
AR056786A1 (es) 2005-11-10 2007-10-24 Smithkline Beecham Corp Compuesto de 1h- imidazo ( 4,5-c) piridin-2-ilo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion, su uso para preparar unmedicamento, uso de una combinacion que omprende al compuesto y al menos un agente antineoplasico para preparar un medicamento y dicha com
DE102008005493A1 (de) 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
AU2009263037B2 (en) 2008-06-26 2011-10-06 Amgen Inc. Alkynyl alcohols as kinase inhibitors
EP2320895A2 (en) 2008-07-03 2011-05-18 Exelixis, Inc. Cdk modulators
US20110183975A1 (en) 2008-10-07 2011-07-28 Yasuhiro Goto Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
US8901313B2 (en) 2011-03-16 2014-12-02 Genentech, Inc. 6,5-heterocyclic propargylic alcohol compounds and uses therefor
TWI663166B (zh) 2013-04-24 2019-06-21 健生藥品公司 新化合物
TWI704146B (zh) 2013-09-26 2020-09-11 比利時商健生藥品公司 用作NIK抑制劑之新的1-(4-嘧啶基)-1H-吡唑並[3,2-c]吡啶衍生物
TWI627173B (zh) 2013-09-26 2018-06-21 比利時商健生藥品公司 作為NIK抑制劑的新穎3-(1H-吡唑-4-基)-1H-吡咯并[2,3-c]吡啶衍生物
EA030908B1 (ru) 2014-10-23 2018-10-31 Янссен Фармацевтика Нв Соединения в качестве ингибиторов nik
MX371151B (es) * 2014-10-23 2020-01-20 Janssen Pharmaceutica Nv NUEVOS DERIVADOS DE TIENOPIRIMIDINA EN CALIDAD DE INHIBIDORES DE LA CINASA INDUCTORA DE NF-kB (NIK).
CA2960335C (en) 2014-10-23 2023-09-19 Janssen Pharmaceutica Nv New pyrazole derivatives as nik inhibitors
ES2715104T3 (es) 2014-10-23 2019-05-31 Janssen Pharmaceutica Nv Nuevos derivados de pirazolopirimidina como inhibidores de nik

Also Published As

Publication number Publication date
AU2015334915A1 (en) 2017-03-30
CA2960574C (en) 2023-03-07
EA201790907A1 (ru) 2017-08-31
US20170334915A1 (en) 2017-11-23
US10822342B2 (en) 2020-11-03
WO2016062790A1 (en) 2016-04-28
KR102523405B1 (ko) 2023-04-18
BR112017007704A2 (pt) 2017-12-19
KR20170068489A (ko) 2017-06-19
CN107074882B (zh) 2019-07-30
EA033237B1 (ru) 2019-09-30
MX371152B (es) 2020-01-20
CA2960574A1 (en) 2016-04-28
EP3209663A1 (en) 2017-08-30
MX2017005284A (es) 2017-07-28
US20190169198A1 (en) 2019-06-06
ES2715104T3 (es) 2019-05-31
IL251778A0 (en) 2017-06-29
BR112017007704B1 (pt) 2023-04-11
JP2017531678A (ja) 2017-10-26
JP6616412B2 (ja) 2019-12-04
US10221180B2 (en) 2019-03-05
EP3209663B1 (en) 2018-12-12
CN107074882A (zh) 2017-08-18
AU2015334915B2 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
IL287113A (en) smyd inhibitors
IL250709B (en) Aminopyrimidines and their use to inhibit jak
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
SG11201605417QA (en) Heterocyclic compounds
IL251420A0 (en) Triazolopyrazinones as pde1 inhibitors
IL251778A0 (en) Novel pyrazolopyrimidine histories as nik inhibitors
IL248895A0 (en) Phosphatidylinositol 3-kinase inhibitors
IL251780A0 (en) New compounds as nik inhibitors
IL251932B (en) Benzylpropargyl ether as nitrification inhibitors
ZA201804688B (en) New substituted cyanoindoline derivatives as nik inhibitors
IL251777A0 (en) New pyrazole histories as nik inhibitors
IL251779B (en) Novel thianopyrimidine histories as nik inhibitors
GB201403536D0 (en) Inhibitor compounds
IL249674B (en) Quinolizinone derivatives as inhibitors of pi3k
IL252866B (en) History of imidazopyridazine as pi3k beta inhibitors
IL246718A0 (en) Hexahydrofuropyrroles as pde1 inhibitors
GB201418154D0 (en) Inhibitors
GB201416462D0 (en) Compound for use
GB201408759D0 (en) Compound for use
GB201409792D0 (en) Compounds for use

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed